Comparison

Semaglutide vs
tirzepatide: how do they differ?

Two molecules built on gut hormones, sold as prescription medicines by two companies and often named together. What each molecule targets, what their labels cover and warn about, what the trials that compared them directly measured, and where they stand with regulators in November 2026.

Short answerCompound research · 8 min read · Updated 18 Nov 2026

Semaglutide and tirzepatide differ first in their targets: semaglutide activates the GLP-1 receptor; tirzepatide activates both the GIP and GLP-1 receptors. Both are in prescription medicines: Novo Nordisk makes semaglutide (Ozempic, Rybelsus, Wegovy) and Eli Lilly makes tirzepatide (Mounjaro, Zepbound). Their US labels carry boxed warnings on thyroid tumours in rodents. Two Lilly-funded phase 3 trials with published results compared them directly: SURPASS-2 and SURMOUNT-5.

Key takeaways

  • Semaglutide is a modified GLP-1 that activates the GLP-1 receptor; tirzepatide is a single peptide based on GIP that activates both the GIP and GLP-1 receptors. Both carry a fatty diacid side chain that binds albumin.
  • Novo Nordisk makes semaglutide (Ozempic, Rybelsus, Wegovy; first US approval December 2017); Eli Lilly makes tirzepatide (Mounjaro, Zepbound; first US approval May 2022).
  • SURMOUNT-5 (NEJM, 2025) randomised 751 adults with obesity, without type 2 diabetes, to either drug for 72 weeks, open-label and funded by Eli Lilly; its primary measure was the percent change in weight.
  • The US labels for both carry a boxed warning on thyroid C-cell tumours in rodents, with human relevance not determined, and overlapping warnings on pancreatitis, gallbladder disease and kidney injury.
  • FDA declared both US shortages resolved (tirzepatide December 2024, semaglutide February 2025), and WADA has both on its 2027 Monitoring Program; neither is named on the 2027 Prohibited List.

01How do semaglutide and tirzepatide differ?

The same questions for both, from the labels and regulators’ records, dated 18 November 2026.

QuestionSemaglutideTirzepatide
What it isA GLP-1 receptor agonist: a modified version of the hormone GLP-1, with a C-18 fatty diacid side chainA GIP receptor and GLP-1 receptor agonist: one peptide based on the GIP sequence, with a C-20 fatty diacid side chain
Formula and massC187H291N45O59; 4113.58 g/molC225H348N48O68; 4813.53 Da
MakerNovo NordiskEli Lilly
US brand namesOzempic, Rybelsus, WegovyMounjaro, Zepbound
First US approvalOzempic, 5 Dec 2017Mounjaro, 13 May 2022
US label usesType 2 diabetes; cardiovascular risk in type 2 diabetes; kidney outcomes in type 2 diabetes with chronic kidney disease; excess body weight (adults, ages 12+); cardiovascular risk in cardiovascular disease with obesity or overweight; MASH (accelerated approval)Type 2 diabetes (adults, children 10+); cardiovascular risk in type 2 diabetes; excess body weight (adults); moderate to severe obstructive sleep apnoea with obesity
European UnionOzempic (2018), Rybelsus (2020), Wegovy (2022), Kayshild (2026)Mounjaro (2022): type 2 diabetes and weight management
United KingdomOzempic, Rybelsus, Wegovy; prescription-only (POM)Mounjaro; prescription-only (POM)
AustraliaSchedule 4; Ozempic on the ARTG since 28 Aug 2019Schedule 4; Mounjaro on the ARTG since 23 Dec 2022
US boxed warningThyroid C-cell tumours in rodents; human relevance “has not been determined”Thyroid C-cell tumours in rats; human relevance “has not been determined”
Outcome trials on the US labelsSUSTAIN 6, SELECT and FLOW, each against placeboSURPASS-CVOT, against dulaglutide
US shortage declared resolved21 Feb 202519 Dec 2024
Sport (WADA)2027 Monitoring Program; not named on the 2027 Prohibited List2027 Monitoring Program; not named on the 2027 Prohibited List

Brand names appear here only as facts from the labels. Research-grade material sold under either name is none of these medicines, and this page does not describe it.

02What is semaglutide?

Semaglutide is a modified version of GLP-1 (glucagon-like peptide-1), a hormone the body releases after eating. Its US label gives it 94% sequence homology to human GLP-1 and says it “selectively binds to and activates the GLP-1 receptor”. A C-18 fatty diacid lets it bind albumin, a blood protein. Novo Nordisk makes it. Labels, trials and status in full: what is semaglutide?

03What is tirzepatide?

Tirzepatide is a single peptide that its US label says “is based on the GIP sequence” and “selectively binds to and activates both the GIP and GLP-1 receptors”. GIP is glucose-dependent insulinotropic polypeptide, a second gut hormone. A C-20 fatty diacid lets it bind albumin. Eli Lilly makes it. Labels, trials and status in full: what is tirzepatide?

04What research compared semaglutide and tirzepatide directly?

Two phase 3 trials with published results compared the two drugs directly, both funded by Eli Lilly, tirzepatide’s maker (ClinicalTrials.gov and PubMed, searched 18 November 2026 under both names, their development codes and brand names). We report each design and what the paper reports for its primary measure.

SURPASS-2SURMOUNT-5
PaperFrías et al., NEJM, 2021Aronne et al., NEJM, 2025
RegistryNCT03987919NCT05822830
Who took part1,879 adults with type 2 diabetes751 adults with obesity, without type 2 diabetes
DesignOpen-label, randomised 1:1:1:1 to one of three tirzepatide levels or semaglutide at one level; phase 3Open-label, randomised 1:1 to tirzepatide or semaglutide, each at the highest level a participant tolerated; phase 3b
Length40 weeks72 weeks
Primary measureChange in HbA1c, a measure of average blood sugar, from baseline to week 40Percent change in weight from baseline to week 72
What the paper reports for the primary measureMean change in HbA1c of −2.01 to −2.30 percentage points across the three tirzepatide levels, and −1.86 with semaglutideLeast-squares mean change of −20.2% (95% CI −21.4 to −19.1) with tirzepatide and −13.7% (95% CI −14.9 to −12.6) with semaglutide (P<0.001)
Adverse eventsMost commonly gastrointestinal and mostly mild to moderate in both groups; serious adverse events in 5% to 7% of tirzepatide groups and 3% of the semaglutide groupMost commonly gastrointestinal in both groups, and mostly mild to moderate

What these trials can and cannot tell you. Both were open-label: participants and investigators knew which drug was given. Both were funded by the maker of one of the two drugs, and Lilly employees are among the authors. Each studied one population for a fixed time; their primary and key secondary measures were blood sugar, weight and waist size, not heart attacks, strokes or deaths. SURMOUNT-5 excluded people with type 2 diabetes; SURPASS-2 enrolled only people with it. In SURPASS-2, semaglutide was tested at a single level. In both trials tirzepatide was tested up to the highest level on its current US labels, while the highest semaglutide level tested is below the highest on the current Ozempic and Wegovy labels.

Other comparisons. A 117-person Lilly study (NCT03951753, Lancet Diabetes & Endocrinology, 2022) compared the two against placebo on insulin release and insulin sensitivity over 28 weeks. ClinicalTrials.gov also lists other randomised studies that give the two drugs to separate groups; each enrolled or plans fewer than 200 people (search of 18 November 2026). How to weigh trials like these: evidence grades.

05What do their labels warn about?

Boxed warning. Every US label for both drugs opens with a warning on thyroid C-cell tumours: in rodents for semaglutide, in rats for tirzepatide. For both, whether this happens in humans, including medullary thyroid carcinoma, is unknown, and both are contraindicated in people with a personal or family history of that cancer or with Multiple Endocrine Neoplasia syndrome type 2.

Warnings and precautions. The Wegovy and Zepbound labels list the same core set: acute pancreatitis, gallbladder disease, hypoglycaemia, acute kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during anaesthesia or deep sedation. The Wegovy label also lists a raised heart rate. Both labels list reports after approval of necrotizing pancreatitis “sometimes resulting in death”. In January 2026 the MHRA said the UK product information for both had been updated on severe acute pancreatitis, “including rare reports of necrotising and fatal pancreatitis”. In February 2026 it said semaglutide “may be very rarely associated with” NAION, an eye condition that can cause vision loss. “Other GLP-1 agonists were not included in this review”, it added, and it “is reviewing any evidence for an association with other GLP-1 agonists”.

Most common adverse reactions. On both labels they are led by nausea, diarrhoea, vomiting, constipation and abdominal pain. Adverse-event rates from different trials are not directly comparable; the labels themselves say so. More: side effects, documented and unknown.

06Where do they stand on compounding, research labels and sport?

Compounding in the US. Both were on FDA’s drug shortage list from 2022, which loosened the limits on compounded copies. FDA declared the tirzepatide shortage resolved on 19 December 2024, after reconsidering a first decision of October 2024, and the semaglutide shortage on 21 February 2025. Its grace periods for copies then ended: for tirzepatide on 19 March 2025 for outsourcing facilities, and for semaglutide on 22 May 2025. On 1 April 2026 FDA said neither appears on its drug shortage list. Compounded drugs “are not FDA approved”, and by 31 May 2026 FDA had 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. FDA says many resemble those for the approved versions, that the numbers are likely under-reported, and that “It is not always possible to determine if the adverse event directly resulted from use of the drug”.

Research-labelled products. FDA says it “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”. More: contamination and mislabeling.

Sport. Neither is named on WADA’s 2027 Prohibited List. WADA has placed both on its 2027 Monitoring Program, which follows substances it “wishes to monitor in order to detect potential patterns of misuse in sport”. On 21 September 2026 it said their status “will remain unchanged for 2027 pending further data becoming available on the possible effects on athletes who take them”. Anti-doping organisations decide how the List applies: peptides and anti-doping.

07What we don’t know

  • How the two compare on heart attacks, strokes, kidney outcomes or death. ClinicalTrials.gov lists observational comparisons, which cannot replace a randomised trial; we found no randomised trial of one against the other on these outcomes (ClinicalTrials.gov and PubMed, 18 Nov 2026).
  • How SURMOUNT-5’s result applies to people with type 2 diabetes, whom it excluded, or beyond 72 weeks.
  • Whether an independent sponsor would find the same. Both published phase 3 comparisons were funded by Eli Lilly and were open-label.
  • How either affects athletes. WADA is waiting for further data.
  • What any product sold outside the licensed supply chain contains. FDA calls research-labelled versions of both “of unknown quality”.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. [SURMOUNT-5 phase 3b trial report: tirzepatide vs semaglutide in adults with obesity without type 2 diabetes.] N Engl J Med, 2025;393(1):26–36 (e-published 11 May 2025). PMID 40353578. pubmed.ncbi.nlm.nih.gov/40353578/
  2. Frías JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. [SURPASS-2 phase 3 trial report: tirzepatide vs semaglutide in type 2 diabetes.] N Engl J Med, 2021;385(6):503–515. PMID 34170647. pubmed.ncbi.nlm.nih.gov/34170647/
  3. Heise T, Mari A, DeVries JH, et al. [Phase 1 mechanistic trial of tirzepatide vs placebo or semaglutide on islet function and insulin sensitivity in type 2 diabetes, NCT03951753.] Lancet Diabetes Endocrinol, 2022. PMID 35468322. pubmed.ncbi.nlm.nih.gov/35468322/
  4. ClinicalTrials.gov. Records NCT05822830 (SURMOUNT-5) and NCT03987919 (SURPASS-2); search for studies with tirzepatide and semaglutide as interventions (87 records; 39 randomised). Registry API v2, read 18 Nov 2026. clinicaltrials.gov/search?intr=tirzepatide%20AND%20semagluti…
  5. U.S. Food and Drug Administration / Novo Nordisk. WEGOVY (semaglutide) prescribing information, revised 06/2026, and OZEMPIC (semaglutide) prescribing information. DailyMed set IDs ee06186f-2aa3-4990-a760-757579d8f77b (SPL 18 Jun 2026) and adec4fd2-6858-4c99-91d4-531f5f2a2d79 (SPL 1 Jun 2026); read 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  6. U.S. Food and Drug Administration / Eli Lilly. ZEPBOUND (tirzepatide) prescribing information, revised 08/2026, and MOUNJARO (tirzepatide) prescribing information. DailyMed set IDs 487cd7e7-434c-4925-99fa-aa80b1cc776b (SPL 28 Aug 2026) and d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (SPL 27 Aug 2026); read 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-43…
  7. U.S. Food and Drug Administration. Drugs@FDA approval history for NDA 209637, 213051, 215256, 218316 (semaglutide) and NDA 215866, 217806 (tirzepatide), with approval letters. openFDA drugsfda endpoint and accessdata.fda.gov; read 18 Nov 2026. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=Basi…
  8. European Medicines Agency. Medicines data (centrally authorised medicines): Ozempic, Rybelsus, Wegovy, Kayshild and Mounjaro records. JSON export, timestamp 18 Nov 2026 06:01 UTC; read 18 Nov 2026. www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
  9. electronic medicines compendium (emc), UK. Summaries of Product Characteristics for Ozempic, Rybelsus, Wegovy and Mounjaro (legal status POM). medicines.org.uk; read 18 Nov 2026. www.medicines.org.uk/emc/product/15483/smpc
  10. Therapeutic Goods Administration. AusPARs for Ozempic (date of entry onto ARTG 28 Aug 2019) and Mounjaro (23 Dec 2022); Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), index entries SEMAGLUTIDE and TIRZEPATIDE, Schedule 4. AusPARs read on the newest Internet Archive captures (tga.gov.au timed out); Poisons Standard PDF from legislation.gov.au; 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  11. Medicines and Healthcare products Regulatory Agency. Drug Safety Updates: strengthened warnings on acute pancreatitis for GLP-1 and dual GLP-1/GIP receptor agonists (29 Jan 2026); semaglutide and NAION (5 Feb 2026). GOV.UK; read 18 Nov 2026 through the GOV.UK content API. www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-du…
  12. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug alert, content current as of 1 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-p…
  13. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  14. World Anti-Doping Agency. The 2027 Monitoring Program (item 6) and the 2027 Prohibited List; WADA publishes 2027 Prohibited List (news release, 21 Sep 2026). Documents downloaded from wada-ama.org, 18 Nov 2026. www.wada-ama.org/en/news/wada-publishes-2027-prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is the difference between semaglutide and tirzepatide?

Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GIP and GLP-1 receptors. They are different molecules from different companies, Novo Nordisk and Eli Lilly, sold as different prescription medicines with different labels.

Has any trial compared semaglutide and tirzepatide directly?

Yes. We found two Lilly-funded, open-label phase 3 trials with published results: SURPASS-2 in 1,879 adults with type 2 diabetes (primary measure HbA1c at 40 weeks) and SURMOUNT-5 in 751 adults with obesity without type 2 diabetes (primary measure percent change in weight at 72 weeks). Smaller randomised studies are registered, and we found no randomised trial of one against the other on heart attacks, strokes or deaths (search of 18 November 2026).

Is Mounjaro the same as Ozempic?

No. Mounjaro contains tirzepatide and is made by Eli Lilly; Ozempic contains semaglutide and is made by Novo Nordisk. Both are prescription medicines, and in the US both are labelled for type 2 diabetes.

Do semaglutide and tirzepatide have the same side effects?

Their US labels list overlapping warnings, including a boxed warning on thyroid C-cell tumours in rodents, pancreatitis, gallbladder disease and kidney injury, and both list nausea, diarrhoea, vomiting, constipation and abdominal pain among the most common reactions. Rates from different trials cannot be compared directly.

Are semaglutide and tirzepatide on the WADA Prohibited List?

Neither is named on WADA’s 2027 Prohibited List. Both are on its 2027 Monitoring Program, and WADA said their status will remain unchanged for 2027 pending further data. Anti-doping organisations decide how the List applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page